{"search_session":{},"preferences":{"l":"en","queryLanguage":"en"},"patentId":"113-293-345-960-154","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"113-293-345-960-154"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":8906,"type":"PATENT","title":"Univ Pennsylvania Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":24238,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8221,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search applicants and owners= \"Univ Pennsylvania\", \"Pennsylvania Univ\", \"Univ Penns*\", \"Penn* Univ\", \"University of Pennsylvania\", \"Pennsylvania University\".
Select more for logical variants
Add to collection
Total patent:
Search Applicants and Owners separately: \"penn* stage univ*\"; \"Penn State\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4149
Search applicants and owners= \"Univ Pennsylvania\", \"Pennsylvania Univ\", \"Univ Penns*\", \"Penn* Univ\", \"University of Pennsylvania\", \"Pennsylvania University\".
Select more for logical variants
Add to collection
Total patent:
Search Applicants and Owners separately: \"penn* stage univ*\"; \"Penn State\"
Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 4149
a) extracting DNA from blood plasma or serum of a human with cancer;\n
b) amplifying or signal amplifying in a qualitative or quantitative fashion a portion of the extracted DNA using primers or probes specific for a tumor-associated non-mutated DNA associated with a target of a monoclonal antibody cancer therapy; and\n
c) detecting the amplified or signal amplified DNA, whereby a human with cancer is selected for the monoclonal antibody cancer therapy."],"number":1,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the target of a monoclonal antibody cancer therapy is a protein associated with cancer."],"number":2,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the DNA is amplified in subpart (b) using an amplification method that is polymerase chain reaction, ligase chain reaction, boomerang DNA amplification, Q-beta replication, transcription-based amplification, isothermal nucleic acid sequence based amplification, self-sustained sequence replication assay, strand displacement activation, or cycling probe technology."],"number":3,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 1, wherein the DNA is detected in subpart (c) using a detection method that is gel electrophoresis, immunological detection, nucleic acid hybridization, Southern blot analysis, electrochemiluminescence, reverse dot blot hybridization, or high performance liquid chromatography."],"number":4,"annotation":false,"title":false,"claim":true},{"lines":["A method of evaluating a human without cancer at risk for cancer or cancer recurrence for a monoclonal antibody therapy, the method comprising the steps of:\n
a) extracting DNA from blood plasma or serum of a human without cancer at risk for cancer or a cancer recurrence;\n
b) amplifying or signal amplifying in a qualitative or quantitative fashion a portion of the extracted DNA using primers or probes specific to a tumor-associated DNA associated with a target of a monoclonal antibody therapy; and\n
c) evaluating for the amplified or signal amplified DNA, whereby a human without cancer at risk for cancer or a cancer recurrence is evaluated for the monoclonal antibody therapy."],"number":5,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the target of a monoclonal antibody therapy is a protein associated with cancer."],"number":6,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the DNA is amplified in subpart (b) using an amplification method that is polymerase chain reaction, ligase chain reaction, boomerang DNA amplification, Q-beta replication, transcription-based amplification, isothermal nucleic acid sequence based amplification, self-sustained sequence replication assay, strand displacement activation, or cycling probe technology."],"number":7,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 5, wherein the DNA is detected in subpart (c) using a detection method that is gel electrophoresis, immunological detection, nucleic acid hybridization, Southern blot analysis, electrochemiluminescence, reverse dot blot hybridization, or high performance liquid chromatography."],"number":8,"annotation":false,"title":false,"claim":true},{"lines":["A method of evaluating a human at risk for having an occult cancer for a monoclonal antibody cancer therapy, the method comprising the steps of:\n
a) extracting DNA from blood plasma or serum from a human at risk for having an occult cancer;\n
b) amplifying or signal amplifying in a qualitative or quantitative fashion a portion of the extracted DNA using primers or probes specific to a DNA associated with a target of a monoclonal antibody cancer therapy; and\n
c) evaluating for the amplified or signal amplified DNA, whereby a human at risk for having an occult cancer is evaluated for the monoclonal antibody cancer therapy."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A method of screening a human with cancer for a monoclonal antibody cancer therapy, the method comprising the steps of:\n
a) extracting DNA from blood plasma or serum of a human with cancer;\n
b) amplifying or signal amplifying in a qualitative or quantitative fashion a portion of the extracted DNA using primers or probes specific for a tumor-associated non-mutated DNA associated with a target of a monoclonal antibody cancer therapy; and\n
c) evaluating for the amplified or signal amplified DNA, whereby a human with cancer is screened for the monoclonal antibody cancer therapy."],"number":10,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}